VIMTALABS

Vimta Labs Share Price

₹1,018.15 +19.25 (1.93%)

03 May, 2025 23:32

SIP TrendupStart SIP in VIMTALABS

Start SIP

Performance

  • Low
  • ₹999
  • High
  • ₹1,048
  • 52 Week Low
  • ₹420
  • 52 Week High
  • ₹1,178
  • Open Price₹1,048
  • Previous Close₹999
  • Volume137,735

Investment Returns

  • Over 1 Month + 0.88%
  • Over 3 Month + 16.25%
  • Over 6 Month + 77.75%
  • Over 1 Year + 91.22%
SIP Lightning

Smart Investing Starts Here Start SIP with Vimta Labs for Steady Growth!

Invest Now

Vimta Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.5
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 2,264
  • P/B Ratio
  • 6.7
  • Average True Range
  • 76.91
  • EPS
  • 30.02
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 9.88
  • RSI
  • 50.94
  • MFI
  • 52.2

Vimta Labs Financials

Vimta Labs Technicals

EMA & SMA

Current Price
₹1,018.15
+ 19.25 (1.93%)
pointer
  • stock-down_img
  • Bearish Moving Average 5
  • stock-up_img
  • Bullish Moving Average 11
  • 20 Day
  • ₹1,012.35
  • 50 Day
  • ₹988.91
  • 100 Day
  • ₹933.08
  • 200 Day
  • ₹824.32

Resistance and Support

1021.73 Pivot Speed
  • R3 1,093.37
  • R2 1,070.68
  • R1 1,044.42
  • S1 995.47
  • S2 972.78
  • S3 946.52

What's your outlook on Vimta Labs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vimta Labs Ltd. offers a wide range of testing, inspection, and analytical services, specializing in pharmaceuticals, food, and environmental testing. Serving clients globally, it provides high-quality, accredited lab services to ensure product safety and regulatory compliance.

Vimta Labs has an operating revenue of Rs. 350.86 Cr. on a trailing 12-month basis. An annual revenue growth of 10% is good, Pre-tax margin of 26% is great, ROE of 17% is exceptional. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 27% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 96 which is a GREAT score indicating consistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Services and a Master Score of A is the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vimta Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-04-28 Audited Results, Dividend & Bonus issue
2025-01-24 Quarterly Results
2024-11-08 Quarterly Results
2024-07-17 Quarterly Results
2024-05-18 Audited Results & Final Dividend
Date Purpose Remarks
2022-06-18 FINAL Rs.2.00 per share(100%)Dividend
2021-06-28 FINAL Rs.2.00 per share(100%)Dividend
View More

Vimta Labs F&O

Vimta Labs Shareholding Pattern

36.7%
0%
3.66%
0.01%
25.17%
34.46%

About Vimta Labs

  • NSE Symbol
  • VIMTALABS
  • BSE Symbol
  • 524394
  • Managing Director
  • Ms. Harita Vasireddi
  • ISIN
  • INE579C01029

Similar Stocks to Vimta Labs

Vimta Labs FAQs

Vimta Labs share price is ₹1,018 As on 03 May, 2025 | 23:18

The Market Cap of Vimta Labs is ₹2263.8 Cr As on 03 May, 2025 | 23:18

The P/E ratio of Vimta Labs is 34.5 As on 03 May, 2025 | 23:18

The PB ratio of Vimta Labs is 6.7 As on 03 May, 2025 | 23:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23